- Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
- Terra L, Beekman MJ, Engelhardt EG, Heemskerk-Gerritsen BAM, Van Beurden M, Roeters Van Lennep JE, Van Doorn HC, De Hullu JA, Van Dorst EBL, Mom CH, Slangen BFM, Gaarenstroom KN, van der Kolk LE, Collée JM, Wevers MR, Ausems MGEM, Van Engelen K, Van De Beek I, Berger LPV, Van Asperen CJ, Gomez Garcia EB, Maas AHEM, Hooning MJ, Aaronson NK, Mourits MJE, Van Leeuwen FE.
- Am J Obstet Gynecol. 2021 Nov 17. pii: S0002-9378(22)02177-9. doi: 10.1016/j.ajog.2022.11.1289. Epub ahead of print.
•• Identifier: NCT03835793: Health After eaRly Menopause Due to Oophorectomy (HARMOny). (ClinicalTrials.gov . Accessed 2022 Nov 17.)
- BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy.
- Soni A, Lin X, Mladenov E, Mladenova V, Stuschke M, Iliakis G.
- Cancers (Basel). 2022 Nov 16;14(22):5619. doi: 10.3390/cancers14225619.
- Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
- Franzese O, Graziani G.
- Cancers (Basel). 2022 Nov 16;14(22):5633. doi: 10.3390/cancers14225633.
- Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru.
- Zavaleta E, Solis N, Palacios MI, Zevallos-Escobar LE, Vasquez Corales E, Bazo-Alvarez JC, Dominguez-Barrera C, Campos A, Wernhoff P, Ekstrøm PO, Møller P, Visnovska T, Hovig E, Balazar-Palacios J, Alvarez-Valenzuela K, Nakken S, Dominguez-Valentin M.
- Cancers (Basel). 2022 Nov 15;14(22):5603. doi: 10.3390/cancers14225603.
- Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.
- Golder A, Nelson L, Tighe A, Barnes B, Coulson-Gilmer C, Morgan RD, McGrail JC, Taylor SS.
- NAR Cancer. 2022 Nov 12;4(4):zcac036. doi: 10.1093/narcan/zcac036.
- PMID: 36381271
- PubMed abstract